What dose should produce weight loss?
1 mg or higher for most patients on Ozempic; Wegovy at 2.4 mg is the FDA-approved weight loss formulation.
How long should it take?
Most patients see measurable loss by week 8-12 at therapeutic doses.
Can you build tolerance?
True tolerance is uncommon; plateau is biological adaptation.
Should I go to a higher dose?
Discuss with your prescriber; dose escalation is often the next step.
Does eating affect results?
Yes substantively; reduced appetite isn't the same as reduced intake.
Does alcohol affect weight loss?
Yes; alcohol calories don't engage satiety mechanisms.
Can sleep affect weight loss?
Yes; sleep deprivation alters ghrelin, leptin, cortisol, and insulin sensitivity.
What if I'm losing inches but not pounds?
Body composition change; muscle gain and fat loss can mask scale change.
When should I see my doctor?
After 12-16 weeks at therapeutic dose without progress, or sooner with side effects or symptoms.
Related guides
- Why Am I Not Losing Weight on Wegovy? The Six Levers Worth Pulling
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Not Losing Weight on Ozempic: A Troubleshooting Checklist
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
- Why Am I Not Losing Weight on Tirzepatide? Decoding Stalled Progress
Sources
- Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
- Rubino D et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance," JAMA, April 2021 (STEP 4)
- Ozempic FDA prescribing information
- Wegovy FDA prescribing information
- Tasali E et al., "Effect of Sleep Extension on Objectively Assessed Energy Intake," JAMA Internal Medicine, March 2022
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- Spiegel K et al., "Brief Communication: Sleep Curtailment Affects Appetite," Annals of Internal Medicine, 2004
- American College of Endocrinology consensus statements on obesity
- National Sleep Foundation guidance on sleep duration
- Centers for Disease Control alcohol use guidelines
- American Thyroid Association screening guidelines
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed prescribers for GLP-1 therapy evaluation and management. This article is educational; it does not replace clinical advice from your prescriber. Individual situations require individual assessment.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP trial data applies to brand Ozempic and Wegovy specifically.
Results Disclaimer. Individual weight outcomes vary significantly. STEP 1 reported a 14.9% mean weight loss at week 68; the distribution included substantial variation. Your result depends on dose, adherence, baseline weight, lifestyle, and individual physiology.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →